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SUMMARY
Papillary thyroid carcinoma (PTC) is the most com-
Previous genetic studies report a high frequency (70%) of acti-
vating somatic alterations of genes encoding effectors in the
mitogen-activated protein kinase (MAPK) signaling pathway,mon type of thyroid cancer. Here, we describe the
genomic landscape of 496 PTCs. We observed a
low frequency of somatic alterations (relative to other
carcinomas) and extended the set of known PTC
driver alterations to include EIF1AX, PPM1D, and
CHEK2 and diverse gene fusions. These discoveries
reduced the fraction of PTC cases with unknown
oncogenic driver from 25% to 3.5%. Combined
analyses of genomic variants, gene expression, and
methylation demonstrated that different driver
groups lead to different pathologies with distinct
signaling and differentiation characteristics. Simi-
larly, we identified distinct molecular subgroups
of BRAF-mutant tumors, and multidimensional ana-
lyses highlighted a potential involvement of onco-
miRs in less-differentiated subgroups. Our results
propose a reclassification of thyroid cancers into
molecular subtypes that better reflect their underly-
ing signaling and differentiation properties, which
has the potential to improve their pathological classi-
fication and better inform the management of the
disease.
INTRODUCTION
The incidence of thyroid cancer has increased 3-fold over the
past 30 years (Chen et al., 2009) and the prevalence of different
histologies and genetic profiles has changed over time (Jung
et al., 2014). All thyroid cancers, except medullary carcinoma,
are derived from follicular cells that comprise the simple unicel-
lular epithelium of normal thyroid. Eighty percent of all thyroid
cancers are papillary thyroid carcinomas (PTCs), named for their
papillary histological architecture. In addition, PTCs encompass
several subtypes, including the follicular variant (FV), character-
ized by a predominantly follicular growth pattern. PTCs are usu-
ally curable with 5-year survival of over 95% (Hay et al., 2002);
however, occasionally they dedifferentiate into more aggressive
and lethal thyroid cancers. Current treatment involves surgery,
thyroid hormone, and radioactive iodine (RAI) therapy (which ex-
ploits thyroid follicular cells’ avidity for iodine).
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et al., 2003; Kimura et al., 2003; Lemoine et al., 1988; Sua´rez
et al., 1988), as well as fusions involving the RET (Grieco et al.,
1990) and NTRK1 tyrosine kinases (Pierotti et al., 1995). These
mutations are almost always mutually exclusive (Soares et al.,
2003), suggesting similar or redundant downstream effects.
The various MAPK pathway alterations are strongly associated
with distinct clinicopathological characteristics (Adeniran et al.,
2006), and gene expression (Giordano et al., 2005) and DNA
methylation profiles (Ellis et al., 2014). Mutations in members of
the phosphoinositide 3-kinase (PI3K) pathway, such as PTEN,
PIK3CA, and AKT1, have also been reported at low frequencies
(Xing, 2013).
We present The Cancer Genome Atlas (TCGA) project results
from a comprehensive multiplatform analysis of 496 PTCs, the
largest cohort studied to date. Clinically aggressive thyroid can-
cers (poorly and undifferentiated carcinomas) were excluded to
maximally develop the compendium of tumor-initiating alter-
ations. While excluding histological types of aggressive tumors
limited some aspects of the study, the homogeneous PTC cohort
allowed robust correlative analyses of multidimensional molecu-
lar data. The relatively quiet PTC genome allowed us to assess
the signaling and differentiation consequences of the common
drivers. Furthermore, the cohort allowed us to define integrated
molecular subtypes that correspond to histology, signaling,
differentiation state, and risk assessment. We put forth that our
results will lead to improved clinicopathologic classification
and management of patients.
RESULTS
Samples, Clinical Data, and Analytical Approach
Tumor samples and matched germline DNA from blood or
normal thyroid from 496 patients included 324 (69.4%) clas-
sical-type (CT), 99 (21.2%) follicular-variant (FV), 35 (7.5%) tall
cell variant (TCV), 9 (2.0%) uncommon PTC variants, and 29
without histological annotation, primarily from nonirradiated
patients (Table S1A available online). We estimated risk of
tumor recurrence based on the 2009 American Thyroid Asso-
ciation guidelines (American Thyroid Association Guidelines
Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer et al., 2009), and assessed mortality risk using MACIS
scores (Hay et al., 1993) (see Supplemental Information). We
generated comprehensive and high-quality molecular data at
TCGA genome sequencing and characterization centers with
one proteomic and six genomic platforms (Table S1B) and
(Roberts et al., 2013) (Mann-Whitney p = 4 3 105), similar to
bladder cancer (Cancer Genome Atlas Research Network,
2014).
The relatively large number of patients in this study and the lowanalyzed the data at multiple genomic data analysis centers
(Table S1C). Although 496 primary tumors were studied, the
number of informative cases varied across platforms, mostly
for technical reasons, and 390 tumors were analyzed on all major
platforms (SNP arrays, exomes, RNA-seq, miRNA-seq, and DNA
methylation).
Our analysis strategy consisted of three parts, each based on
integrating several molecular data sets. First, we identified
somatic mutations that included single nucleotide variants, small
insertions and deletions, gene fusions, and copy-number alter-
ations in order to characterize the genomic landscape of PTC
and identify driver events in cases without any previously known
driver (i.e., the so-called ‘‘dark matter’’ of the PTC genome).
Next, we focused on the consequences of the driver mutations.
We developed a gene expression signature of samples with
these mutations and characterized tumors based on this signa-
ture. We then determined the differential signaling conse-
quences of BRAFV600E and RAS mutations, the most common
pathogenic mutations in the cohort, using protein and mRNA
expression data. Finally, we used the molecular data to derive
molecular classifications of PTC and integrated these classifi-
cations with data related to genotype, signaling, differentiation,
and risk.
Somatic Single Nucleotide Variants and Insertions
and Deletions
Whole exome DNA sequencing of 402 (of 496) tumor/normal
pairs (average depth-of-coverage; 97.03 for tumors, 94.93 for
normals) showed a low somatic mutation density (0.41 nonsy-
nonymous mutations per Mb, on average) (Figures 1A and
S1A; Table S3) relative to other cancers (Lawrence et al., 2014;
Lawrence et al., 2013). Mutation density correlated with age
(Pearson correlation p = 5.2 3 1018, Figure S1B), risk of recur-
rence (Kruskal-Wallis test p = 3.4 3 104), and MACIS score
(Pearson correlation p = 43 1015, Figure S1C). To compensate
for the confounding effect of age at diagnosis, we regressed the
effect of age from mutation density and found that the asso-
ciation of risk with age-corrected mutation density remained
(Kruskal-Wallis test p = 9.7 3 103); MACIS scores did not (p =
0.19, Figure S1C). This association was maintained for the CT
cohort (p = 0.0044), but not for other variants (Figure S1D). The
correlation between mutation density and age suggests age
should be used as a continuous variable in risk stratification
(Bischoff et al., 2013), instead of a threshold of 45 years used
in many staging systems.
Mutation densities were not associated with other variables,
like genotype or radiation exposure (Mann-Whitney p = 0.579
and p = 0.173, respectively; Figure S1E). TCVs had the highest
mutation density (Figure S1F), consistent with their known
aggressive behavior. Five BRAFV600E mutant tumors with
aggressive histologic features had higher mutation densities
(Figures S1E and S1G).
Ten tumors with the highest mutation densities (>1/Mb) were
enriched for mutations associated with the APOBEC processbackground mutation density provides the statistical power to
detect significantly mutated genes (SMGs) in as low as 3% of
cases (>90% power for 90% of genes) (Lawrence et al., 2014).
MutSig (Lawrence et al., 2013) detected seven SMGs (q < 0.1)
(Figure 1C and Table S2) with four of the seven in < 3% of
patients. SMGs included the MAPK-related genes, BRAF,
NRAS,HRAS, andKRAS, whichwere virtually mutually exclusive
(Figure 1C, Fisher’s exact test p = 1.1 3 105, MEMo [Ciriello
et al., 2012] corrected p < 0.01, Table S4A) in 300/402 (74.6%)
patients. The 248 (61.7%) BRAF mutations were mostly V600E
substitutions (Figures 1C and S2A and Table S3C). Somatic sin-
gle nucleotide variants (SSNVs) were identified in 52 patients
(12.9%) within codons 12 and 61 of RAS genes (Figures 1C
and S2B and Table S3D). We observed strong associations
between BRAF and RAS mutation status and histology, with
BRAFV600E characterizing CT and TCV and RAS mutations
characterizing FV (Figures 1B and 1C and Table S3E). These
observations confirm the critical role of MAPK pathway alter-
ations in PTC and illustrate that having more than one mutation
confers no clonal advantage.
MutSig also identified EIF1AX (eukaryotic translation initiation
factor 1A, X-linked) as significantly mutated (q = 5.33 108; Fig-
ure 1C and Table S3B). EIF1AX encodes a protein that mediates
transfer of Met-tRNAf to 40S ribosomal subunits to form the 40S
preinitiation complex for protein translation. Six (1.5%) muta-
tions (Figure S2C) were identified in tumors lacking other known
driver mutations (Fisher’s exact test of EIF1AX versus RAS/
BRAF, p = 0.013) with one exception: one case with three driver
mutations in KRAS, BRAF, and EIF1AX; here the KRASmutation
was clonal (cancer cell fraction estimated at 100% with 95%
CI [56%–100%]), while EIF1AX and BRAF were subclonal at
76% (38%–100%) and 53% (22%–94%) cancer cell fractions,
respectively (see Supplemental Information). The near-mutual
exclusivity of EIF1AX alterations with MAPK pathway mutations
(Figure 1C), together with recurrent mutations in other tumors
(Forbes et al., 2011; Martin et al., 2013), suggests that EIF1AX
is a novel cancer gene in PTC.
The two remaining SMGs (PPM1D, CHEK2, Figures S2D
and S2E) encode interacting proteins related to DNA repair
(Oliva-Trastoy et al., 2007) and occurred concomitant with
MAPK-pathway driver mutations (Figure 1C). Germline PPM1D
mutations are associated with breast and ovarian cancer predis-
position and may impair p53 function (Kleiblova et al., 2013).
Although not statistically significant, there were 8 additional
DNA repair-related mutations in 26 (6.5%) tumors, all mutually
exclusive (Figure S3A, MEMo corrected p = 0.24). Tumors car-
rying these mutations had a significantly higher median mutation
density (Table S5A, Mann Whitney p = 0.022), although not after
age-adjustment (p = 0.111), and were enriched with high-risk
patients (Fisher’s exact test p = 0.018). These observations,
together with our finding of a mutated network of FANCA-asso-
ciated genes (see ‘‘Integrated Analysis of Somatic Alterations’’
section), suggest that acquisition of a defect in DNA repair
represents a mechanism for development of aggressive PTC.
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We also observed alterations in other cancer genes, pathways
and functional groups (chromatin remodeling, PI3K, WNT and
tumor suppressor genes). Although not statistically significant,
they are known to play a role in thyroid cancer pathogenesis
2013). Mutations of tumor suppressor genes (TP53, RB1, NF1/
2, MEN1, and PTEN) were identified in 15/402 (3.7%) tumors
(Figure S3C). In addition, two genes that may be tumor suppres-
sors were near significance: (1) ZFHX3, a zinc finger homeobox
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Figure 1. Landscape of Genomic Alterations in 402 Papillary Thyroid Carcinomas
(A) Mutation density (mutations/Mb) across the cohort.
(B) Tumor purity, patient age, gender, history of radiation exposure, risk of recurrence, MACIS score, histological type, and BRS score.
(C) Number and frequency of recurrent mutations in genes (left) ranked by MutSig significance (right), gene-sample matrix of mutations (middle) with TERT
promoter mutations (bottom).
(D) Number and frequency of fusion events (left), gene-sample matrix of fusions across the cohort (middle).
(E) Number and frequency of SCNAs (left), chromosome-sample matrix of SCNAs across the cohort (middle) with focal deletions in BRAF and PTEN (bottom),
GISTIC2 significance (right).
(F) Driving variant types across the cohort. Samples were sorted by driving variant type with dark matter on the left.
See also Figures S1, S2, S3, S4 and Tables S1, S2, S3, S4A, S5A, S5B, and S5E.and progression (Xing, 2013). We identified 93 mutations within
57 epigenetic regulatory genes in 80/402 (20.0%) tumors, 9 of
which possessed more than one mutation (Figure S3D). Muta-
tions in MLL (1.7%), ARID1B (1.0%), and MLL3 (1%) were
most frequent (Figures 1C and S3D). In the PI3K and PPARg
pathways, we observed 20 nearly mutually exclusive mutations
in PTEN, AKT1/2, and PAX8/PPARG (Figure S3E), representing
4.5% (18/402) of cases. Mutations of five WNT pathway-related
genes were found in 6/402 (1.5%) tumors (Figure S3B), a lower
frequency than reported for aggressive tumor types (Xing,
678 Cell 159, 676–690, October 23, 2014 ª2014 The Authorstranscription factor (Minamiya et al., 2012), in 7/402 (1.7%) tu-
mors (q = 0.79); and (2) BDP1,which may regulate AKT signaling
(Woiwode et al., 2008), in 5/402 (1.2%) tumors (q = 0.58). Finally,
mutations in thyroid-related genes were infrequent: 11/402
(2.7%) mutations in thyroglobulin, 2/402 (0.5%) mutations in
thyroid-stimulating hormone receptor (TSHR). No mutations in
thyroid hormone receptor genes (TRHA and TRHB) were found.
We identified TERT promoter mutations in 36 (9.4%) of 384
informative tumors, with 27 (7.0%) C228T, 1 (0.3%) C228A,
and 8 (2.1%)C250T substitutions. Thesemutationswere present
in PTCs of all histological types. TERT promoter mutations had
modest association with mutation drivers (Fisher’s exact test
p = 0.029) and arm-level somatic copy-number alterations (p =
0.023), but not BRAF mutations or gene fusions. They showed
TERT promoter mutations occurred in less-differentiated PTCs
(lower TDS values, see ‘‘Signaling and Differentiation’’ section)
(Kruskal-Wallis test p = 4.2 3 105, Figure 2C). These associa-
tions are consistent with published results (Melo et al., 2014;
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Figure 2. TERT Promoter Mutations and Clonality Assessment of
Driver Mutations
(A–C) Association of TERT promoter mutations with (A) risk of recurrence, (B)
MACIS score, and (C) thyroid differentiation score (TDS). See also Table S2.
(D) Mutation cancer cell fraction distribution. The majority of all mutations,
including driver mutations BRAF, NRAS, HRAS, KRAS, and EIF1AX, have a
calculated cancer cell fraction close to 1.0, indicating their presence all tumor
cells.strong associations with older age, MACIS scores (Kruskal-
Wallis test p = 2.6 3 109, and p = 1.3 3 1011, Figure 2B,
respectively), and high risk of recurrence (Fisher’s exact test
p = 7 3 108, Figure 2A), within the entire cohort, and these
associations remained within the BRAFV600E tumors. Finally,Xing et al., 2014) and suggest that molecular diagnostic assess-
ment of TERT promoter mutations may be used to identify high
risk patients.
A recent report suggested that BRAFV600E mutations in PTC
are often present only in a small subset of the cancer cells
(Guerra et al., 2012), information relevant to therapeutic appli-
cation of BRAF inhibitors. To address this issue, we used the
ABSOLUTE package (Carter et al., 2012) to estimate the cancer
cell fraction (CCF) of mutations in BRAF, NRAS, HRAS, KRAS,
and EIF1AX (see Supplemental Information). In our study, all of
these driver mutations were present in the majority of tumor
cells (Figure 2D), i.e., they are largely clonal. Our results instead
confirm other studies showing homogeneous cancer cell immu-
nohistochemical staining with BRAFV600E-specific antibodies
(Ghossein et al., 2013).
We performed targeted sequencing validation experiments
on a subset of 318 tumors at 333 mutated sites. Two hundred
sixty-four of 265 (99.6%) of mutations in driver genes were
confirmed. We also carried out targeted validation on a random
set of 54 mutations, of which 49 (91%) were confirmed, for an
overall validation rate of 96%.
Gene Fusions
Chromosomal rearrangements and translocations contribute to
PTC pathogenesis (Xing, 2013). We identified both known and
novel fusions, including new partners of previously described
fusions, in 74 (15.3%) of 484 informative cases, based on multi-
ple platforms (Figure 3). Fusions were mutually exclusive with
each other and with BRAF, RAS, and EIF1AXmutations (Fisher’s
exact test p = 4.9 3 1043; Figures 1C, 1D and S3F). Fusion-
positive tumors were associated with younger age of diagnosis
(Wilcoxon rank-sum test p = 0.005), but not with risk of recur-
rence (Fisher’s exact test p = 0.55) or age-corrected mutation
density (rank-sum test p = 0.341, Table S5A).
RET fusions were most frequent (33/484, 6.8%) (Table S5B
and Figure S3F); however, less frequent than previously reported
in sporadic or radiation-associated PTC (Ricarte-Filho et al.,
2013). We identified four novel unique RET fusions that pre-
served the kinase domain (Figure 3A and Table S5B).
Fusions involving BRAF have been identified in PTC (Ciampi
et al., 2005) and other cancers. Inmelanoma, these events define
a molecular subclass with distinct response to MEK inhibition
(Hutchinson et al., 2013). In our cohort, we identified 13/484
(2.7%) BRAF fusions with diverse gene partners (Figure 3A and
Table S5B); three tumors exhibited the SND1/BRAF gene fusion
seen in a gastric cancer cell line (Lee et al., 2012). Some fusions
supported BRAF signaling with expression and conservation
of its kinase domain (MKRN1/BRAF), while others suggested
an alternative activating mechanism. Six of nine BRAF fusions
were validated by independent PCR experiments, while PCR
evidence for the other three was inconclusive. These diverse
fusions, together with the BRAF point mutations and indels
described above, illustrate the various possible mechanisms of
activating BRAF and highlight its oncogenic importance in PTC.
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We identified PAX8/PPARG fusions in 4/484 (0.8%) tumors.
Originally found in follicular carcinomas (Kroll et al., 2000),
PAX8/PPARG translocations have been reported with low fre-
quency in PTC, especially FV. ETV6/NTRK3 and RBPMS/
Figure 3. Candidate ‘‘Driver’’ Gene Fusions
in Papillary Thyroid Carcinoma
(A) RNA expression fusion plots for representative
novel candidate genes involving RET, BRAF, ALK,
NTRK3, and LTK fusions. Each gene in the fusion
plot is drawn 50 to 30, exon specific relative
expression data are represented with low (blue)
and high expression (red), and the kinase domain
is mapped with a green box. The pairs of numbers
across the links indicate the number of split reads
and paired-end supporting reads from RNA-seq.
(B) Circos plots (http://circos.ca) of RET, BRAF,
and NTRK3 fusions. Red links represent recurrent
fusions, black nonrecurrent.
See also Figures S3F and Table S5B.
evidence for a close relationship between
FV and follicular neoplasms in which
SCNAs are more common (Wreesmann
et al., 2004a).
tations, with 4 cases
The SCNA-22q-del c
riched for FV (p < 0
that loss of CHEK2 anNTRK3 fusions were uncovered in 6/484 (1.2%) tumors. These
fusions are more prevalent in radiation-induced thyroid cancers
but have lower prevalence in sporadic PTC (Ricarte-Filho et al.,
2013). THADA fusions were identified in 6/484 (1.2%) tumors.
Fusions involving ALK presented in 4/484 (0.8%) tumors,
including EML4/ALK (Figure 3A), which is observed in lung
adenocarcinomas and rare thyroid cancers (Kelly et al., 2014),
suggesting opportunities for targeted inhibition of ALK. In
addition, two cases had FGFR2 fusions and two cases had
nonrecurrent fusions of MET and LTK (Table S4B).
Somatic Copy-Number Alterations
Somatic copy-number alterations (SCNAs) were identified in
135 (27.2%) of 495 informative tumors. These 135 cases
were significantly enriched in cases with no driver mutation or
fusion (Fisher’s exact test p = 4.4 3 104; Figures 1C, 1D, and
1E), suggesting that SCNAs may also drive PTC. Arm-level
alterations occurred significantly more frequently in FV than in
CT subtypes (Figure S4A) (FDR < 0.1, p < 0.008), providing
680 Cell 159, 676–690, October 23, 2014 ª2014 The AuthorsUnsupervised clustering of chromo-
somal arm-level alterations defined four
distinct classes (Figure S4B). The largest
class (72.9%) lacked significant gains
or losses (SCNA-quiet), reflecting the
highly differentiated nature of PTC; this
group was not enriched for any partic-
ular genotype or histologic type. A sec-
ond class (9.9%) was characterized by
an isolated loss of 22q (SCNA-22q-del),
a region that includes NF2 and CHEK2
and reported to be lost with significant
frequency in PTC (Kjellman et al.,
2001). Seventy tumors had 22q loss
and five tumors possessed CHEK2 mu-
containing both mutations (p = 0.0035).
ohort contained few TCV and was en-
.05) (Figure S4C). This result suggests
d/or the NF2 tumor suppressor may be
ticularly in the FV subtype. A third classimportant in PTC, par
(14.8%) was characterized by a few SCNA events and gain of
1q (SCNA-low-1q-amp), was enriched for TCV (p < 0.0001)
and BRAF mutations (p < 0.05) (Figure S4C), and was asso-
ciated with significantly higher MACIS scores (p < 0.0001)
(Figure S4D), risk profiles (Figure S4E), and tumor stage
(Figure S4F), consistent with reports of 1q gains in aggressive
PTC (Wreesmann et al., 2004b). The final and smallest class
(2.4%) was defined by a higher frequency of focal gains and
losses (SCNA-high).
We found few significantly recurring focal alterations using
GISTIC2 (Mermel et al., 2011). In 5/13 tumors withBRAF fusions,
we detected by SNP array the resulting focal alterations at 7q34.
Five tumors with 10q23.31 deletions lacked PTEN expression
(Figure S4G). We also found single case amplifications contain-
ing oncogenic driver genes (e.g., FGFR3). Together, these
results, in the context of SSNVs and fusions, suggest that
SCNAs may represent both tumor-initiating and progression-
related events in PTC.
Integrated Analyses of Somatic Alterations
Next, we sought to identify additional genes that may harbor
driver mutations (point mutations, fusions or copy-number
changes) that did not meet significance, by searching within
tions, so-called ‘‘dark matter’’ samples, for the presence of novel
potential driver alterations. SSNVs involving drivers accounted
for 299 (73.6%) cases. Mutually exclusive fusions increased
the number of cases with drivers to 358 (89.0%). Three mutuallyprotein-protein interaction networks for subnetworks enriched
with frequently mutated genes. To this end, we applied the
HotNet2 algorithm (M.D.M. Leiserson, F. Vandin, H.T. Wu,
J.R. Dobson, J.V. Eldridge, J.L. Thomas, A. Papoutsaki, Y. Kim,
B. Niu, M. McLellan, M.S. Lawrence, A.G. Perez, D. Tamborero,
Y. Cheng, G.A. Ryslik, N. Lopez-Bigas, G. Getz, L. Ding, and
B.J. Raphael, unpublished data) and identified 17 significantly
mutated subnetworks (p < 0.004, Table S5C and Figure S5A).
As expected, the largest subnetwork (16 genes) included four
knownmembersof theMAPKsignalingpathway (BRAFand three
RAS genes) and 12 additional genes (Figure S5B). Some of these
additional genes (e.g., RAP1GAP) displayed mutations that were
mutually exclusive with BRAF (SSNVs, indels and fusions) and
RAS, andmay represent additionalMAPKdrivers. Othermutated
genes in this subnetwork (e.g., PIK3CA) overlapped with
BRAFV600E and may alter the biology of these cancers by acti-
vating PI3K signaling, a hypothesis that requires validation.
Other HotNet2 subnetworks significantly overlapped with
knownpathways (TableS5CandFiguresS5C–S5E). Identification
of the ECM-receptor interactions pathway is consistent with the
role of ECM microenvironment in PTC (Nucera et al., 2011). The
finding of a FANCA-associated protein complex subnetwork pro-
vides additional evidence for DNA repair playing a role in PTC.
We used network-based stratification (NBS) (Hofree et al.,
2013) to discover three somatic mutation-based PTC subtypes
(NBS1-3, Figures S6A–S6C). As expected, a strong association
with histologic subtype was found, with a significant association
between NBS1 and FV histology (Figure S6B, b, Fisher’s exact
test p < 2 3 1016). The subtypes were also significantly asso-
ciated with lymph node status, extrathyroidal extension, stage
and risk of recurrence (Figure S6B, a, c–e, Fisher’s exact test
p = 4.43 104, 3.13 107, 3.83 103, 8.23 106, respectively),
as well as other molecular characteristics (Figure S6C). In order
to identify somatic events that characterize each subnetwork,
we applied the HotNet algorithm to each NBS subtype (Fig-
ure S6D and Table S5D). Subtype NBS1 was associated with
perturbations in RAS, PTEN, PPARG, and TSHR. Subtype
NBS2 was associated with alterations in RET and related genes
such as NTRK3. Subtype NBS3 appears to be predominantly
BRAFV600E-associated. These results confirm three broad clas-
ses of PTC determined by the common drivers.
We also looked for the presence of viral pathogens in PTC
using two independent methods to assess the RNA-seq data:
PathSeq (Kostic et al., 2011) and BioBloom Tools (Chu et al.,
2014). We identified two tumors with hepatitis B virus (HBV)
and one tumor with human papillomavirus 45 (HPV45) at relative
frequencies exceeding 0.1 viral reads per million human reads
(RPM) for PathSeq and 0.2 RPM for BBT (see Supplemental
Information and Tables S4G–S4I), indicating that viral pathogens
are unlikely significant contributors to PTC pathogenesis.
‘‘Dark Matter’’ Summary
Starting with 402 cases with informative exome DNA sequence
data, we examined tumors that lacked apparent driver muta-exclusive focal deletions (2 PTEN and 1 BRAF) brought the num-
ber of cases to 361 (89.8%). Mutually exclusive arm-level SCNAs
were present in 27 additional cases, which were mostly FV.
Although we cannot pinpoint the driving genes, if we assume
that some of these SCNAs indeed act as drivers, the total num-
ber of cases with apparent drivers increased to 96.5%, leaving
14 (3.5%) as ‘‘dark matter’’ cases. By reviewing events in these
cases, we observed additional potential drivers such as APC,
ATM,NF1, and SPOP,mutations of chromatin remodeling genes
(e.g., MLL) and potential gene fusions (Table S5E). Including
these events and considering arm-level SCNAs as drivers, we
have identified putative cancer drivers in 397/402 PTCs (98.8%).
Signaling and Differentiation
PTC is a MAPK-driven cancer that has two mutually exclusive
drivers with distinct signaling consequences: BRAFV600E and
mutated RAS. Tumors driven by BRAFV600E do not respond to
the negative feedback from ERK to RAF (since it signals as a
monomer), resulting in high MAPK-signaling (Pratilas et al.,
2009). Conversely, tumors driven by RAS and RTK fusions
signal via RAF dimers that respond to ERK feedback, resulting
in lower MAPK-signaling. This differential signaling results in
profound phenotypic differences. For example, expression of
genes responsible for iodine uptake and metabolism are greatly
reduced in BRAFV600E tumors, in contrast to the ‘‘RAF-dimer’’
tumors in which expression of these genes is largely preserved
(Durante et al., 2007). These observations, together with the
relatively low number of other genomic alterations, allow for a
clear view of the signaling and transcriptional outputs of these
two primary drivers. The distinct profile of expression of genes
involved in thyroid hormone biosynthesis that we observed
between BRAFV600E and RAS-driven tumors is recapitulated
closely in mouse PTC models induced by knock-in mutations
of BrafV600E or HrasG12V (Charles et al., 2011; Franco et al.,
2011), suggesting that these arise as a consequence of the
constitutive activation of these drivers.
To explore these relationships across our cohort, we devel-
oped a BRAFV600E-RAS score (BRS) to quantify the extent to
which the gene expression profile of a given tumor resembles
either the BRAFV600E or RASmutant profiles. Using 391 samples
with both exome and RNA sequencing data, we compared
BRAFV600E-mutated and RAS-mutated tumors to derive a 71-
gene signature. Correlations with this signature were used to
derive a continuous measure (1 to +1) with BRAFV600E-like
(BVL) PTCs being negative and RAS-like (RL) PTCs positive
(see Supplemental Information). As expected, this signature
showed strong separation of the BRAFV600E and RAS mutant
tumors (Figures S7A and S7B).
We then used the BRS as a reference continuous scale from
most BVL to most RL to interrogate the signaling consequences
of the other, less common, mutations (Figures 4A and 4B). All
BRAF mutations other than BRAFV600E exhibited RL behavior,
including oneBRAFK601E, a splice-site mutation and three indels.
This is consistent with previous observations that BRAFK601E
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occurs in FV tumors that are mostly RL-PTCs (Park et al., 2013).
All of the BRAF fusions were BVL. Four of the six EIF1AX muta-
tions were RL, one neutral, and one weakly BVL. All of the PAX8/
PPARG fusions were RL, consistent with their prevalence in
with TDS across all tumors and within the BRAFV600E cohort.
We discovered that the TDS was associated with global expres-
sion changes, significantly correlated and anticorrelated with
thousands of genes in both cohorts (Figures S7F and S7G). We
Figure 4. The BRAFV600E-RAS Score
(A–E) Thyroid samples (A) (n = 391) were ranked byBRAFV600E-RAS score (BRS), withBRAFV600E-like andRAS-like samples having negative (1 to 0) and positive
scores (0 to 1), respectively. The BRS is strongly associated with: (B) driver mutation status; (C) thyroid differentiation score (TDS); (D) single data-type clusters;
and (E) histology and follicular fraction. The RAS-like samples (normalized score > 0, in red on the top bar) consistently emerged as a distinct subgroup char-
acterized by a higher TDS. See also Figures S6, S7A, and S7B and Tables S2 and S4B.follicular-patterned tumors. Nearly all of the RET fusions were
weakly BVL, and the NTRK1/3 and ALK fusions were largely
neutral.
Next, we focused on thyroid differentiation, which plays a cen-
tral role in thyroid cancer. We summarized the expression levels
of 16 thyroid metabolism and function genes (Table S5F), which
were highly correlated across our cohort, and produced a single
metric, designated the Thyroid differentiation score (TDS). The
TDS and BRSmeasures were highly correlated across all tumors
(Spearman = 0.78, p = 3.1 3 1080), despite being derived
from different gene sets. This correlation was mainly driven by
RL-PTCs having relatively high TDS values. The BRAFV600E
PTC cohort, considered a homogeneous group in numerous
studies, showed a wide range of TDS values (Figure 5), and
maintained the TDS and BRS correlation, albeit to a lesser de-
gree (Spearman = 0.38, p = 3.0 3 109, Figures 4, 5, and S7C–
S7E). To gain insights regarding the observed TDS variation,
we identified other genes whose expression levels correlated
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microarray data (Giordano et al., 2005) (Figure S7H). Next, to
test whether differences in the TDS within the BRAFV600E mutant
cohort were associated with subtle architectural changes, we
histologically graded the tumors (Figure S7I) and showed
that TDS was indeed correlated with grade (Kruskal-Wallis
test p = 4 3 106, Figure S7J). TDS also correlated with risk
(p = 2 3 105) and MACIS (Spearman correlation p = 1.3 3
106) but only weakly with tumor purity (p = 1.5 3 103) (Fig-
ure S7J), indicating that the observed differences in TDS and
global expression levels were not strongly influenced by varia-
tions in levels of tumor stroma or lymphocyte infiltration. These
results support the validity of the TDS and BRS and illustrate
that, while independently derived, these measures reflect
similar biological properties that are profoundly reflected by
gene expression in PTC.
Although the TDS was correlated with many genes, among
the most correlated were several genes with cancer relevance
(TFF3, KIT, PVRL4, and FHL1, q = 8.02 3 1030, 5.62 3 1029,
4.08 3 1013, and 7.52 3 10115, respectively, Figures 5, S7F,
and S7G). Among miRs with cancer relevance, miR-21, miR-
146b, andmiR-204were highly correlatedwith the TDS (Figure 5,
An integrated view of our TDS analysis (Figure 5) summarizes
how RL-PTCs result in highly differentiated tumors enriched
for follicular histology with distinct gene expression and DNA
methylation patterns. Conversely, BVL-PTCs result in predomi-
Figure 5. Role of Thyroid Differentiation in Papillary Thyroid Carcinomas
Thyroid differentiation score (TDS) across the cohort with tumors sorted by driver mutation and TDS. Below TDS are the BRAFV600E-RAS score (BRS), ERK
signature, histological type, MACIS score, risk of recurrence, driver mutations, and gene expression data for nine thyroid genes used to derive the TDS (TG, TPO,
SLC26A4 [pendrin], SLC5A5 [Na/I symporter], SLC5A8 [apical iodide transporter], DIO1, DIO2, DUOX1, and DUOX2), four selected mRNAs correlated to TDS,
and three selectedmiRs correlated to TDS. FeaturedmRNA (except for 16 thyroid genes) andmiRNA genes were selected based on Spearman correlation to TDS
in the BRAFV600E cohort (*) and the full cohort (**) (see Supplemental Information). See also Figures S7C–S7J and Table S5F.S7F, and S7G), withmiR-21 being themost negatively correlated
miR in both the entire and BRAFV600E cohorts. miR-21 and
miR-146b are oncogenic miRs in several tumor types (Di Leva
et al., 2014) and miR-204 is downregulated in several tumors
types and may be a tumor suppressor (Imam et al., 2012). We
subsequently identified variable expression of these miRs in
distinct miR clusters with different TDS and BRS values (see
‘‘Molecular Classification’’ section).
Our data demonstrate significant gene expression variation
across the BRAFV600E cohort, which may account for the range
of differentiation observed and may explain the uncertainty
regarding the prognostic and predictive power of BRAFV600E
mutation (Xing et al., 2013). Dedifferentiation likely plays a role
in dampening responses to RAI therapy and is consistent with
observations that RAI-refractory metastases are enriched for
BRAFV600E mutants (Sabra et al., 2013). Although other factors
are likely involved, our results support the view that potent
constitutive activation of the MAPK transcriptional output by
oncogenic BRAFV600E downregulates the expression of genes
involved in iodine metabolism (Chakravarty et al., 2011; Franco
et al., 2011). Of note, the loss of differentiation within the
BRAFV600E cohort is likely smaller than that observed in histo-
logically aggressive thyroid cancers.nantly less-differentiated tumors enriched for classical and tall
cell histology, with distinct gene expression and DNA methyl-
ation patterns. Further assessment of BRS and TDS might be
useful in the setting of a clinical trial and even pathology practice
using immunohistochemistry.
To better understand the downstream signaling effects of
the main driver events (BRAFV600E, RAS), we examined mRNA
expression and protein and phosphoprotein levels of various
signaling pathways. We used a 52-gene signature derived by
inhibiting MEK in a BRAFV600E melanoma cell line (Pratilas
et al., 2009) to assess the ERK (and MAPK) activation level.
BRS was highly correlated to ERK activation level (i.e., ERK
score, see Supplemental Information); BVL-PTCs showed over-
activation of the pathway (Figure S8A) and increased expression
of DUSP genes (Figure 6). Note that, although the two scores are
highly correlated, they were derived independently and have no
genes in common. In wild-type cells, ERK induces a negative
feedback on effectors upstream in the pathway, resulting in
impairment of RAF dimerization. Because BRAFV600E signals
as a monomer, it is insensitive to feedback leading to ERK
overactivation (Poulikakos et al., 2010).
RET fusions consistently had BVL phenotype, high MAPK
activity and were associated with low pS338-CRAF and
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pS299-ARAF (Figure S8B), consistent with preferential signaling
via BRAF homodimers (Mitsutake et al., 2006). RL-PTCs had
concurrent activation of PI3K/AKT andMAPK signaling, the latter
mostly through c-RAF phosphorylation (Figure 6). Despite having
refine the classification of PTC into molecular subtypes and
associate them with clinically relevant parameters. To this end,
we leveraged the BRS and TDS measures to inform the relation-
ships between tumor cluster, histology, genotype, signaling, and
A B
Figure 6. Downstream Signaling of BVL and RL PTCs
(A) MAPK and PI3K pathways are differentially activated in the BVL and RL PTCs.
(B)BRAFV600E-mutated cases show robust activation of MAPK signaling resulting in higher output of the ERK transcriptional program, represented in particular by
DUSP (DUSP4, 5 and 6)mRNAs. Thismay be due to insensitivity of BRAFV600E to ERK inhibitory feedback. By contrast,RAS-like tumors activated bothMAPK and
PI3K/AKT signaling, as shown by higher pAKT levels in these tumors. The mechanism by which RAS-like tumors activated MAPK signaling was distinct from that
ofBRAFV600E tumors, as they had higher CRAF phosphorylation, consistent with engagement of RAF dimers. Paradoxically, RL-PTCs had higher phosphorylation
of the ERK substrate p90RSK, which was associated with mTOR activation, likely through phosphorylation and consequent inhibition of TSC2. RL-PTCs also
showed activation of an antiapoptotic program, characterized by S112-BAD phosphorylation (a target of P90RSK) andBCL2 overexpression. See also Figures S8
and Tables S4B and S4F.lower MAPK activity than BVL-PTCs, RL-PTCs showed sig-
nificantly higher phosphorylation of p90RSK, a direct ERK
substrate. Activation of p90RSK was associated with robust
inhibition of TSC2, a distinguishing hallmark of the two functional
classes, and likely to induce mTOR. Elevated p90RSK in the
RL-PTCs was also associated with phosphorylation of its sub-
strate BAD, and with concurrent BCL2 overexpression, leading
to antiapoptotic signaling (Figure 6 and Table S4B). Finally, we
used TieDIE (Paull et al., 2013) to assess differential pathway
activation between BVL-PTC and RL-PTC (see Supplemental
Information). This approach identified the small GTPase RHEB,
a known regulator of mTOR activity (Groenewoud and Zwartk-
ruis, 2013), as a contributing factor to the differences observed
between BVL-PTC and RL-PTC (Figure S8C, Table S4F and
Data S1). These findings confirm many of the known signaling
changes induced by BRAFV600E and RAS mutations in PTC,
provide a framework for MAPK downstream activity in tumors
with other driver alterations, and importantly shed new light on
the role of p90RSK as a crucial crossroad for MAPK, mTOR,
and BCL2 signaling in RAS-driven tumors.
Molecular Classification
The comprehensive and multiplatform molecular data and large
sample size in this study provide an opportunity to derive and
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Applying unsupervised clustering methods to four genomic
data sets yielded a different number of subtypes for each data
set: five for mRNA expression, six for miR expression, four
for DNA methylation, and four for protein expression (Figures
S9A–S9D). All clustering results were consistent with two
meta-clusters that separated the BRAFV600E-driven tumors
(BVL-PTCs) from ones with RASmutations (RL-PTCs), recapitu-
lating the BRS-partitioning and association with histological sub-
types (Figures 4 and S9A). We used StratomeX (Streit et al.,
2014) to visually highlight these relationships (see THCA publi-
cation page, https://tcga-data.nci.nih.gov/docs/publications/
thca_2014/); in particular, the significant distinction between
BVL-PTCs and RL-PTCs that is evident in each of the molecular
data sets (Table S5G). We also applied SuperCluster (see
Supplemental Information) to the four genomic data sets, which
supported the overarching separation of BVL-PTCs and RL-
PTCs (Figure S9E).
Next, we focused on the internal structure reported by
different data types for these two meta-clusters. The RL-PTC
group was associated with a single cluster in all data sets except
DNA methylation (described below). Overall, this group was
characterized by FV histology, relatively low risk of recurrence,
distinct mRNA expression profiles with lower expression of
immune response genes, higher expression of miR-182-5p and
miR-183-5p, low levels of fibronectin, VHL, and CHK2 proteins,
and high expression of claudin-7, TIGAR, and BRCA2 proteins
(Figures 7, S9B and S9D). RL tumors were highly differentiated
Figure 7. Unsupervised Clusters for
miRNA-seq Data
Heatmap showing discriminatory miRs (5p or 3p
mature strands) with the largest 6% of metagene
matrix scores (see Supplemental Information), as
well as miR-204-5p, 221-3p, and 222-3p, which
were highlighted in correlations to BRS and TDS
scores (see Figure S10D). The scalebar shows log2
normalized (reads-per-million, RPM), median-
centered miR abundance. miR names in red are
discussed in the text. Gray vertical lines in the
clinical information tracks mark samples without
clinical data, and in the mutation tracks gray lines
identify samples without sequence data. See
also Figures S9, S10, and Tables S4C, S4D, S4E,
S5G, and S6.
fusions, mutational densities, histological
and risk profiles, age, and BRS and TDS
values (Table S5G). The most striking
relationship between subtypes was that
mRNA and miR cluste
THCA publication pag
fied by SuperCluster (and associated with younger patients. The DNA methylation
data partitioned these tumors into two clusters: the larger,
termed Meth-follicular, showed few methylation changes com-
pared to normal thyroid, while the other, termed the Meth-CpG
Island cluster, was characterized by hypermethylation of a large
number of CpG sites in islands and shores (Figure S9C). The sig-
nificance of this distinction is unclear, although the Meth-CpG
Island cluster tended to have high tumor purity with less lympho-
cyte infiltration and stromal cells (Figure S9C, d).
The different data sets partitioned the BVL-PTC group into
different numbers of subtypes (from two based on DNA methyl-
ation data to five based on miR data), which did not overlap with
each other such as to form a fully consistent lower level partition-
ing of BVL-PTCs (Figures 4 and S9). Regardless of which data
set was used, the clusters were significantly different based on
parameters like proportions of driver mutations and genemRNA-cluster 5 was nearly fully
embedded within miR-cluster 6 (86/106
mRNA-cluster 5 tumors were part of the
144 tumors in miR-cluster 6; Fisher’s
exact test p = 1.3 3 1036). This mRNA
cluster, which we termed tall cell-like,
contained most of the TCV tumors
(74%), had the highest frequency of
BRAFV600E mutations (78%), and the
lowest BRS and TDS values (i.e., the
strongest BVL phenotype and least differ-
entiated). Since the tall cell-like cluster
was associated with more advanced
stage (see THCA publication page) and
higher risk (Table S5G), this may be clini-
cally relevant. We again used StratomeX
to highlight the relationships between
rs with recurrence risk and histology (see
e). The tall cell-like cluster was also identi-
Figure S9E).
ysisIntegrated miR Anal
Given the increased role of miRs in determining cancer pheno-
type, we further examined the association between miR expres-
sion, molecular subtypes, and clinical parameters. In addition
to miR-182 and miR-183 in the RL-PTC group, several other
cancer-relevant miRs were relatively abundant in other miR clus-
ters (Figures 7 and S9B). These included oncomiRs (miR-21 and
miR-146b) and tumor suppressor miRs (let-7 family, miR-204,
and miR-375). OncomiRs miR-221 and miR-222 were reported
to play a role in PTC aggressiveness (Mardente et al., 2012)
and, in our data, were associated with less-differentiated tumors
(Figures 7 and S10D, b).
We focused integrative analysis on miR-21, miR-146b, and
miR-204 because they were epigenetically regulated, correlated
with BRS and TDS, and/or differentially expressed between
PTCs and normal thyroid, as well as between clusters derived
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from miRNA-seq data (Figures S9B, S10A, S10B, and S10F).
miR-21 expression correlated with highly variable DNA methyl-
ation (Figure S10C), defined the tall cell-like mRNA and DNA
methylation Meth-classical-1 clusters and was highly correlated
PTC somatic genetic landscape has the potential to even further
enhance the care of these patients. This study also offers conclu-
sive evidence that mutated BRAF and other driving mutations
are clonal events present in the majority of cells within tumorswith low BRS and TDS values (Figures 7 and S10D). miR-21 is a
regulator of several cancer-related genes (Di Leva et al., 2014).
In our data, using Regulome Explorer’s pairwise associations,
its expression was anticorrelated with expression of cancer-
promoting genes and regulators of apoptosis (e.g., PDCD4) (Fig-
ure S10E). PDCD4 is a miR-21 target gene reported to function
as a tumor suppressor in diverse tumors (Zhu et al., 2008). These
observations raise the possibility that increased miR-21 expres-
sion via epigenetic dysregulation may contribute to the clinically
aggressive nature of this BVL-PTC subcluster and may partly
explain the aggressive nature of TCV.
miR-146b expression exhibited similar patterns of differential
expression and correlations to DNA methylation, BRS, and
TDS (Figures 7, S10C, and S10D), and likely influenced expres-
sion of, for example, IRAK1,KIT and TRAF6 (Figure S10E). These
results are consistent with observations that miR-146b is asso-
ciated with risk of recurrence and promotes cell migration and
invasion (Chou et al., 2013).
miR-204 expression, while less influenced by DNA methyl-
ation, was preferentially lost in miR clusters 5 and 6, the two
BVL-PTC subclusters with the lowest BRS and TDS values (Fig-
ures 7 and S9B). This is consistent with data from other tumors,
i.e., miR-204 functions as a tumor suppressor and high levels
suppress cell migration, invasion, and EMT (Qiu et al., 2013).
These results suggest that loss of miR-204 may also contribute
to aggressive PTCs with BRAFV600E mutations. Collectively,
our results are consistent with prior studies and suggest that
miRs may regulate fundamental aspects of the PTC phenotype,
i.e., signaling, differentiation, invasion and metastasis, by fine-
tuning gene expression.
DISCUSSION
This study illustrates the dominant role and mutually exclusive
nature of driving somatic genetic alterations, be they SSNVs,
indels, or fusions, in the MAPK and PI3K pathways in PTC. The
relative low overall density of somatic mutations may be the
biological basis for the indolent clinical behavior of PTC. We
discovered new driver mutations in PTC, either entirely novel in
this cancer (EIF1AX) or novel alterations of known drivers (RET,
BRAF and ALK fusions). As a result of these discoveries, the
‘‘dark matter’’ of the PTC genome has been reduced substan-
tially from 25% to less than 4%, which should have profound
consequences for preoperative cancer diagnosis in thyroid nod-
ules. Molecular testing of mutation hotspots, rearrangements,
and gene expression using fine-needle aspiration specimens
has become an effective diagnostic tool to more precisely select
patients for thyroid surgery (Alexander et al., 2012; Nikiforov
et al., 2011), thereby reducing the number of thyroidectomies
done for benign nodules and tumors (Nikiforov et al., 2013),
and determining the extent of initial thyroid surgery (i.e., lobec-
tomy versus total thyroidectomy) (Yip et al., 2014). Through these
advances, molecular diagnostics has improved the care of
patients with thyroid nodules and cancer. Our expansion of the
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BRAF, and ALK), expanding the biological basis for targeted
therapy.
Beyond the driver mutations, we discovered individual genes
(CHEK2, ATM, and TERT) and sets of functionally related genes
(chromatin remodeling) with alterations or expression patterns
(miR-21 andmiR-146b) that define clinically-relevant subclasses
and may contribute to loss of differentiation and tumor progres-
sion. Specifically, increased expression of miR-21 was associ-
ated with a known aggressive form of PTC (tall cell variant) and
may be a critical event in its pathogenesis. Similarly, TERT pro-
moter mutations identified a subset of aggressive, less-differen-
tiated PTCs, consistent with recent reports (Melo et al., 2014;
Xing et al., 2014). Our study also indicates that BRAFV600E PTC
represents a diverse group of tumors, consisting of at least four
molecular subtypes, with variable degrees of thyroid differentia-
tion. Collectively, our results suggest thatBRAFV600E PTC should
not be considered a homogeneous group in clinical studies and
that future studies should include molecular components de-
signed to capture the breadth of genetic diversity among PTCs.
We demonstrate striking signaling differences in RAS- and
BRAFV600E-driven PTCs. In particular, BVL-PTCs signal pre-
ferentially through MAPK while RL-PTCs signal through both
MAPK and PI3K. The relative simplicity of the PTC genome,
with dominant mutually exclusive driving events, together with
the large cohort and comprehensive data analyzed in this study
enabled us to clearly dissect these signaling differences.
Our overarching conclusion is that RL-PTCs and BVL-PTCs
are fundamentally different in their genomic, epigenomic, and
proteomic profiles. This is consistent with their known histo-
logical differences and the published literature. However, the
breadth and depth of our integrative findings have wide implica-
tions for basic pathobiology, tumor classification schemes, and
traditional and targeted therapies. This view is supported by
recent data suggesting differential response to a MEK inhibitor
related to thyroid cancer genotype (Ho et al., 2013). We feel,
based on the strength of our multidimensional genomic findings,
that a pathologic reclassification of follicular-patterned thyroid
lesions is justified. There was a time when follicular-patterned
PTCs (i.e., RL-PTCs) were classified as follicular carcinomas.
Perhaps the time has come to revise the classification of thyroid
cancer to reunite the FV of PTC with follicular carcinomas.
Moreover, a refined classification scheme that more accurately
reflects the genotypic and phenotypic differences between and
within RL and BVL PTCs would lead to more precise surgical
andmedical therapy, especially as thyroid cancer therapy enters
the realm of precision medicine.
EXPERIMENTAL PROCEDURES
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from local institutional review boards. DNA, RNA, and protein were purified
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